CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >
Study on the inhibitory effect of artemether liposome on Toxoplasma gondii proliferation in vitro
Received date: 2023-01-29
Revised date: 2023-04-18
Online published: 2023-09-06
Supported by
National Natural Science Foundation of China(82272366);National Natural Science Foundation of China(81971955);Natural Science Foundation of Guangdong Province(2021A1515012115);Natural Science Foundation of Guangdong Province(2019A1515011667);Shenzhen Municipal Natural Science Foundation(JCYJ20220530145002006);Graduate Education Innovation Plan Project of Guangdong Province(2021SFKC003);Undergraduate Teaching Quality Engineering Project of Sun Yat-sen University, China(SYSU Undergraduate Education [2022]91);Undergraduate Teaching Quality Engineering Project of Sun Yat-sen University, China(SYSU Undergraduate Education [2022]93)
Objective To investigate the inhibitory effect of artemether liposome (ARM-Lip) on Toxoplasma gondii tachyzoite proliferation in vitro. Methods Human cervical cancer cells (Hela cells) were cultured in 96-well flat bottom cell culture plate, with 100 μl cell culture medium in each well containing 1 × 104 Hela cells. Setting ARM-Lip groups with different concentrations (3.125, 6.250, 12.500, 25.000, 50.000, 100.000, 200.000, 400.000 and 800.000 μmol/L), a control group (only containing 1 × 104 human cervical cancer cells), and a blank group (only containing culture medium). A total of 100 μl corresponding drugs were added to each well in the ARM-Lip groups after 24 h, and 10 μl CCK-8 solution was added to each well after 48 h. A microplate reader was used to detect the absorbance at 450 nm wavelength after 1 h (A-value) to calculate the cell survival rate and 50% inhibitory concentration (IC50) of ARM-Lip. Hela cells were infected with T. gondii green fluorescence-expressing RH (RH-GFP) straintachyzoites, and co-cultivated with different concentrations of ARM-Lip to screen safe concentrations of ARM-Lip those rendered higher than 50% cell survival rate. Through setting of 400 μmol/L sulfadiazine (SDZ) group, and untreated group, the proliferations of tachyzoites were observed under fluorescence microscope after cultured for 24, 48, and 72 h. The average fluorescence gray scale values of each group at 48 h were measured and the group having optimal concentration of ARM-Lip was selected. After Giemsa staining, the parasitophorous vacuoles in Hela cells and the growth of T. gondii tachyzoites were observed and counted. One-way ANOVA was used for inter-group comparison, and the least significant difference (LSD) test was used for pairwise comparison. Results ARM-Lip at a concentration of 25 μmol/L or lower had little toxic effect on Hela cells, and its IC50 was 285.1 μmol/L. Treated with 100.000, 200.000, 400.000, and 800.000 μmol/L ARM-Lip, the cell survival rate was 89.03%, 76.30%, 42.12% and 27.85%, respectively. ARM-Lip concentrations of 6.250, 12.500, 25.000, 50.000, and 100.000 μmol/L were selected to conduct subsequent experiments. Under a fluorescence microscope, a large amount of T. gondii RH-GFP strain tachyzoites were observed in the untreated group, with normal morphology and high intensity of green fluorescence. As the concentration of ARM-Lip was increased, the intensity of green fluorescence was gradually decreased. The optimal concentration for ARM-Lip to inhibit T. gondii growth in vitro was 100.000 μmol/L and the optimal action time was 48 h. After cultured for 48 h, the average gray scale values of the untreated group, ARM-Lip group (100.000 μmol/L) and SDZ group were 89.92 ± 1.12, 35.74 ± 1.55 and 7.34 ± 0.60 (F = 7 916.301, P < 0.01). Compared with the untreated control group, the average grey scale values of the ARM-Lip group and SDZ group were significantly decreased (t = 81.247, 123.831, both P < 0.01); compared with the ARM-Lip group, the average gray scale value of the SDZ group was significantly decreased (t = -42.584, P < 0.01). After Giemsa staining, the numbers of parasitophorous vacuoles of untreated group, ARM-Lip group, and SDZ group were 28.667 ± 2.658, 16.667 ± 0.817 and 12.667 ± 1.211 (F = 135.652, P < 0.01); the numbers T. gondii tachyzoites in each group were 176.167 ± 13.273, 105.333 ± 7.789 and 70.167 ± 5.947 (F = 192.763, P < 0.01). Compared with the untreated control group, the numbers of parasitophorous vacuoles of ARM-Lip group and SDZ group were significantly decreased (t = 0.083, 0.063, both P < 0.01), and the numbers of T. gondii tachyzoites of ARM-Lip group and SDZ group were significantly decreased (t = 0.014, 0.009, both P < 0.01). The numbers of parasitophorous vacuoles and T. gondii tachyzoites in the SDZ group were significantly fewer than in the ARM-Lip group (t = -0.500, -0.057, both P < 0.01). Conclusion ARM-Lip have relatively good safety and can inhibit the proliferation of T. gondii tachyzoites in vitro, whereas its effectiveness remains insufficient when compared with SDZ.
ZHAO Ziqi , LV Fangli . Study on the inhibitory effect of artemether liposome on Toxoplasma gondii proliferation in vitro[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023 , 41(4) : 446 -451 . DOI: 10.12140/j.issn.1000-7423.2023.04.008
| [1] | Montoya JG, Liesenfeld O. Toxoplasmosis[J]. Lancet, 2004, 363(9425): 1965-1976. |
| [2] | Alday PH, Doggett JS. Drugs in development for toxoplasmosis: Advances, challenges, and current status[J]. Drug Des Devel Ther, 2017, 11: 273-293. |
| [3] | Ben-Harari RR, Goodwin E, Casoy J. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review[J]. Drugs R D, 2017, 17(4): 523-544. |
| [4] | Paquet C, Yudin MH. No.285-toxoplasmosis in pregnancy: prevention, screening, and treatment[J]. J D'obstetrique Gynecol Du Can, 2018, 40(8): e687-e693. |
| [5] | Chao CC, Anderson WR, Hu S, et al. Activated microglia inhibit multiplication of Toxoplasma gondii via a nitric oxide mechanism[J]. Clin Immunol Immunopathol, 1993, 67(2): 178-183. |
| [6] | Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii[J]. Eukaryot Cell, 2007, 6(11): 2147-2156. |
| [7] | Zhang YH, Wang LJ, Gan LL, et al. Research progress in clinical application of artemether and its preparations[J]. Chongqing Med, 2014, 43(29): 3967-3970. (in Chinese) |
| (张亚红, 王丽娟, 甘淋玲, 等. 蒿甲醚及其制剂的临床应用研究进展[J]. 重庆医学, 2014, 43 (29): 3967-3970.) | |
| [8] | Wang ZL, Hu YX, Fu TX, et al. Clinical observation of antimalarial drugs for imported cases of Plasmodium falciparum[J]. Parasit Infect Dis, 2016, 14(3): 129-132. (in Chinese) |
| (王忠磊, 胡颖新, 付婷霞, 等. 蒿甲醚、青蒿琥酯等抗疟药治疗输入性恶性疟临床观察[J]. 寄生虫病与感染性疾病, 2016, 14(3): 129-132.) | |
| [9] | Yao JM, Cai Y, Shi XH, et al. Early treatment of Toxoplasma gondii infections with artemether in mice[J]. Chin J Parasitol Parasit Dis, 2003, 21(6): 371. (in Chinese) |
| (姚俊敏, 蔡玥, 施晓华, 等. 蒿甲醚早期治疗实验小鼠弓形虫病的初步观察[J]. 中国寄生虫学与寄生虫病杂志, 2003, 21(6): 371.) | |
| [10] | Shah S, Dhawan V, Holm R, et al. Liposomes: advancements and innovation in the manufacturing process[J]. Adv Drug Deliv Rev, 2020, 154/155: 102-122. |
| [11] | Chimanuka B, Gabri?ls M, Detaevernier MR, et al. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice[J]. J Pharm Biomed Anal, 2002, 28(1): 13-22. |
| [12] | Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice[J]. Clin Microbiol Rev, 2018, 31(4): e00057-e00017. |
| [13] | Liang ZH, Xu L. Studies on the enzyme cytochemistry of Toxoplasma gondii and the influence of artemether[J]. Chin J Parasitol Parasit Dis, 1995, 13(3): 182-184. (in Chinese) |
| (梁志慧, 徐麟鹤. 弓形虫的酶细胞化学及蒿甲醚对其影响的研究[J]. 中国寄生虫学与寄生虫病杂志, 1995, 13(3): 182-184.) | |
| [14] | Liu Y, Yang SY, Zhang YH, et al. Ultrastructural study on effects of artemether on Toxoplasma gondii in mice[J]. Chin J Parasit Dis, 1996(3): 207-208. (in Chinese) |
| (刘杨, 杨少毅, 张永浩, 等. 蒿甲醚对小鼠体内弓形虫作用的超微结构研究[J]. 中国寄生虫病防治杂志, 1996(3): 207-208.) | |
| [15] | Walker DM, Oghumu S, Gupta G, et al. Mechanisms of cellular invasion by intracellular parasites[J]. Cell Mol Life Sci, 2014, 71(7): 1245-1263. |
| [16] | Zhang JL, Si HF, Li B, et al. Current situation and research progress of anti-Toxoplasma drugs[J]. Chin Vet Sci, 2019, 49(8): 1054-1060. (in Chinese) |
| (张吉丽, 司鸿飞, 李冰, 等. 抗弓形虫药物应用现状与研究进展[J]. 中国兽医科学, 2019, 49(8): 1054-1060.) | |
| [17] | Jiang YQ, Dong YJ, Zhou FJ, et al. Research progress on artemisinin and its derivatives[J]. Chin Tradit Herb Drugs, 2022, 53(2): 599-608. (in Chinese) |
| (蒋沅岐, 董玉洁, 周福军, 等. 青蒿素及其衍生物的研究进展[J]. 中草药, 2022, 53(2): 599-608.) | |
| [18] | Li XY, Li XT, Wang YL. Preparation and characterization of APGA modified artemether liposomes[J]. Chin Tradit Herbal Drugs, 2019, 50(7): 1569-1575. (in Chinese) |
| (李秀英, 李学涛, 王颖莉. 氨基蝶呤修饰的蒿甲醚脂质体的制备工艺研究[J]. 中草药, 2019, 50(7): 1569-1575.) | |
| [19] | Zhai BT, Ma YY, Xie SC, et al. Effects of monensin sodium, sulfadiazine and artemether against Toxoplasma RH strain tachyzoites in vitro and in vivo[J]. Chin Vet Sci, 2020, 50(5): 624-630. (in Chinese) |
| (翟斌涛, 马元元, 谢世臣, 等. 莫能菌素钠、磺胺嘧啶和蒿甲醚体内外抗弓形虫RH株速殖子的效果分析[J]. 中国兽医科学, 2020, 50(5): 624-630.) |
/
| 〈 |
|
〉 |